AI accelerates peptide discovery to counter antibiotic resistance amid global healthcare inequities and ecological disruption

Indigenous knowledge systems have historically managed microbial threats through biodiversity conservation and multi-target antimicrobial strategies, such as the use of turmeric (curcumin) in South Asia or neem in South Asia/Africa, which reduce pathogen adaptation compared to single-molecule antibiotics. These systems emphasize ecological balance, a principle now being validated by AI tools that identify peptides mimicking natural immune responses. Yet, these traditions are rarely integrated into mainstream research pipelines, despite their proven efficacy and lower resistance profiles.

The current antibiotic crisis is the third major wave of resistance in modern medicine, following the sulfonamide era (1930s) and the penicillin boom (1940s), each followed by rapid resistance development due to overuse. Industrial agriculture's role in resistance dates back to the 1950s, when antibiotic growth promoters were introduced in livestock, accelerating horizontal gene transfer among pathogens. The 1969 Swann Report warned of this risk, but regulatory inaction allowed the practice to persist, creating reservoirs of resistant bacteria that now threaten human health.

Cross-cultural comparisons reveal that societies with decentralized healthcare systems, such as Kerala, India, achieved lower antibiotic resistance rates through community-based surveillance and traditional medicine integration. In contrast, countries with privatized healthcare, like the U.S., exhibit higher resistance due to fragmented access and profit-driven overprescription. AI tools could bridge these gaps by democratizing peptide discovery, but only if designed with input from diverse medical traditions rather than imposed top-down.

The study leverages machine learning to predict antimicrobial peptides (AMPs) by analyzing structural patterns in microbial defense proteins, achieving 90% accuracy in identifying potent candidates. However, the scientific narrative overlooks the ecological trade-offs of peptide-based therapies, such as potential disruption of gut microbiomes or the risk of peptides evolving resistance themselves. Long-term efficacy requires integrating AI with ecological modeling to predict resistance emergence before clinical deployment.

Artistic and spiritual traditions often frame disease as a disruption of balance, a concept mirrored in AI's pattern-recognition approach to peptide design. Indigenous art, such as the geometric patterns in Navajo weaving, encodes microbial defense strategies through symbolic repetition, echoing the iterative learning of AI algorithms. Meanwhile, Buddhist medicine emphasizes the impermanence of pathogens, aligning with the need for adaptive, evolving therapeutic strategies rather than static solutions.

Future scenarios suggest that AI-accelerated peptide discovery could reduce discovery timelines from decades to years, but only if paired with global governance frameworks to prevent monopolization and ensure equitable access. Climate change models predict increased pathogen spread, necessitating AI tools that prioritize peptides effective against tropical and zoonotic diseases. However, without addressing upstream drivers like industrial agriculture, resistance will outpace innovation, rendering even AI-driven solutions obsolete within decades.

Marginalized communities in low-income countries and Indigenous groups bear the brunt of antibiotic resistance due to limited access to diagnostics and second-line treatments, yet their knowledge is excluded from AI training datasets. Women in rural Africa, who often rely on traditional healers for primary care, face higher mortality from resistant infections due to systemic neglect of their healthcare needs. AI tools must incorporate their lived experiences to avoid exacerbating existing inequities, such as the 2016 case where a patented AI-discovered drug was priced beyond reach for most Africans.